ArticleFrontiers in oncology2026
Tamoxifen-induced neutropenia and leukopenia in a breast cancer patient: a case report and literature review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tamoxifen is a cornerstone of endocrine therapy for hormone receptor-positive breast cancer. While its common side effects are well-documented, severe hematological toxicities such as neutropenia and leukopenia are extremely rare. Case presentation: We report a case of a 37-year-old premenopausal woman with hormone receptor-positive breast cancer who developed neutropenia and leukopenia three months after initiating adjuvant tamoxifen (20 mg/day). Despite transient improvements with supportive therapies (leucogen tablets and Compound Ejiao Jiang), cytopenias persisted. Tamoxifen was discontinued and switched to ovarian function suppression (leuprolide) plus an aromatase inhibitor (exemestane). Within four weeks, neutrophil and leukocyte counts normalized and remained stable over six months of follow-up. Conclusion: This case highlights the importance of recognizing tamoxifen-induced hematological toxicity. Regular blood count monitoring is essential, and in premenopausal women intolerant to tamoxifen, switching to ovarian function suppression plus an aromatase inhibitor is a safe and effective alternative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.